Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.34 |
| ▸ | TKT | P29401 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983862 | 0.75 | CYP11B1 (0.39) | CTSBCYP11B1CYP11B2TKTCYP3A4 | |
| SCHEMBL25574410 | 0.73 | NOS1 (0.33) | CTSB | |
| SCHEMBL24261178 | 0.72 | CYP11B1 (0.38) | CTSBCYP11B1CYP11B2TKTCYP3A4 | |
| SCHEMBL23990848 | 0.70 | CYP11B1 (0.38) | CTSBCYP11B1CYP11B2TKTCYP3A4 | |
| SCHEMBL24261177 | 0.68 | CYP11B1 (0.36) | CTSBCYP11B1CYP11B2TKTCYP3A4 | |
| SCHEMBL23661902 | 0.68 | CYP11B1 (0.44) | CTSBCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL21282958 | 0.68 | CYP11B1 (0.38) | CTSBCYP11B1CYP11B2TKTCYP3A4 | |
| SCHEMBL24900110 | 0.67 | TBXAS1 (0.50) | CTSBCYP11B1CYP11B2CYP3A4 | |
| SCHEMBL1630903 | 0.67 | — | — | |
| SCHEMBL30390414 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | CTSB 1534/4885CYP11B1 1065/4885CYP11B2 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.